Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
133%(4 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
3
60%
Ph not_applicable
2
40%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
N/ANon-phased studies
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 23 (60.0%)
N/A2 (40.0%)

Trials by Status

completed360%
terminated120%
withdrawn120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer

NCT00093379
terminatednot_applicable

Radiation Therapy for Heterotopic Ossification Prophylaxis Acutely After Elbow Trauma

NCT00991887
completedphase_2

Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma

NCT01004874
withdrawnnot_applicable

Proton Therapy for High Risk Prostate Cancer

NCT01811810
completedphase_2

Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas

NCT00597402

Clinical Trials (5)

Showing 5 of 5 trials
NCT00093379Phase 2

Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer

Completed
NCT00991887Not Applicable

Radiation Therapy for Heterotopic Ossification Prophylaxis Acutely After Elbow Trauma

Terminated
NCT01004874Phase 2

Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma

Completed
NCT01811810Not Applicable

Proton Therapy for High Risk Prostate Cancer

Withdrawn
NCT00597402Phase 2

Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas

Completed

All 5 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
5